{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:27:24Z","timestamp":1793608044240,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.euroneuro.2026.112786","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:35:34Z","timestamp":1774352134000},"page":"112786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6629-0619","authenticated-orcid":false,"given":"Suresh","family":"Durgam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie R.","family":"Earley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Kozauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Lakkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2026.112786_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257129","article-title":"Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies","volume":"16","author":"Ali","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0002","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1017\/S1092852923002213","article-title":"Importance of achieving rapid treatment response in major depressive disorder","volume":"28","author":"Alva","year":"2023","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0003","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0004","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21r14328","article-title":"Impact of major depressive disorder on comorbidities: a systematic literature review","volume":"83","author":"Arnaud","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0005","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0006","article-title":"Prescribing information","year":"2025","journal-title":"Intra-Cellular Therap."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0007","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/phar.2404","article-title":"Akathisia and newer second-generation antipsychotic drugs: a review of current evidence","volume":"40","author":"Chow","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0008","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0009","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1176\/appi.ajp.2013.13030325","article-title":"Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses","volume":"171","author":"Cuijpers","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"DeHert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0012","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40263-019-00625-3","article-title":"Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-analysis","volume":"33","author":"Demyttenaere","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0013","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.25m15848","article-title":"Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial","volume":"86","author":"Durgam","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0014","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1176\/appi.ajp.20250292","article-title":"Adjunctive lumateperone in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial","volume":"182","author":"Durgam","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"GBD 2019 Mental Disorders Collaborators; Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0016","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1007\/s12325-023-02622-x","article-title":"The economic burden of adults with major depressive disorder in the United States (2019)","volume":"40","author":"Greenberg","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0017","series-title":"Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0018","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.886918","article-title":"Glutamatergic system in depression and its role in neuromodulatory techniques optimization","volume":"13","author":"Khoodoruth","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0020","first-page":"e188","article-title":"Effect of inadequate response to treatment in patients with depression","volume":"16","author":"Knoth","year":"2010","journal-title":"Am. J. Manage. Care"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0021","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/07067437241245384","volume":"69","author":"Lam","year":"2024","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-018-1625-y","article-title":"Understanding the emotions of patients with inadequate response to antidepressant treatments: results of an international online survey in patients with major depressive disorder","volume":"18","author":"Mago","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0023","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41572-023-00454-1","article-title":"Major depressive disorder","volume":"9","author":"Marx","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0024","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0165-0327(02)00120-9","article-title":"Differentiating moderate and severe depression using the Montgomery\u2013\u00c5sberg depression rating scale (MADRS)","volume":"77","author":"M\u00fcller","year":"2003","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0026","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063095","volume":"13","author":"Pigott","year":"2023","journal-title":"BMJ Open."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0028","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0029","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40273-021-01040-7","article-title":"The growing burden of major depressive disorders (MDD): Implications for researchers and policy makers","volume":"39","author":"Proudman","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0030","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.OT19037BR3","article-title":"Inadequate response to treatment in major depressive disorder: augmentation and adjunctive strategies","volume":"81","author":"Rafeyan","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0031","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.psychres.2016.08.035","article-title":"Impact of major depressive disorder, distinct subtypes, and symptom severity on lifestyle in the BiDirect Study","volume":"245","author":"Rahe","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0032","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0033","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","article-title":"Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis","volume":"9","author":"Semahegn","year":"2020","journal-title":"Syst. Rev."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0034","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0036","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0037","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk. Manage."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"10","author":"Spielmans","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0039","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.06.009","article-title":"Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: a dopamine D(1) receptor dependent mechanism","volume":"62","author":"Titulaer","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/YIC.0000000000000246","article-title":"Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder","volume":"34","author":"Vieta","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0041","series-title":"Prescribing Information","year":"2022"},{"key":"10.1016\/j.euroneuro.2026.112786_bib0042","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","article-title":"Second generation antipsychotics in the treatment of major depressive disorder: an update","volume":"52","author":"Wang","year":"2016","journal-title":"Chonnam. Med. J."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0043","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/YIC.0000000000000226","article-title":"The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies","volume":"33","author":"Weiss","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0044","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1590\/1414-431X20143672","article-title":"Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder","volume":"47","author":"Wen","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.euroneuro.2026.112786_bib0045","doi-asserted-by":"crossref","first-page":"pyv060","DOI":"10.1093\/ijnp\/pyv060","article-title":"Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis","volume":"18","author":"Zhou","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X26000271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X26000271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:37:23Z","timestamp":1793605043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X26000271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"alternative-id":["S0924977X26000271"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2026.112786","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2026.112786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112786"}}